Ocugen CEO to Present at NobleCon21, Highlighting Gene Therapy Progress
ByAinvest
Thursday, Nov 20, 2025 7:03 am ET1min read
OCGN--
Ocugen CEO Dr. Musunuri will present at NobleCon21 on December 3, 2025, highlighting the company's progress towards its goal of three BLAs in three years and near-term catalysts in 2026. The presentation will focus on Ocugen's modifier gene therapy platform and its potential to address significant unmet medical need for blindness diseases. The session will also include one-on-one meetings with investors and a high-definition video webcast available on Ocugen's website and Noble Capital Markets' Conference website.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet